Rivastigmine (Exelon) for dementia in patients with Parkinson's disease

Authors


Amos D. Korczyn, Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Tel-Aviv 69978, Israel
Tel.: 972-3-6973528
Fax: 972-3-640-9113
e-mail: neuro13@post.tau.ac.il

Abstract

Objectives – To study the efficacy of cholinesterase inhibitors in the treatment of dementia in patients with Parkinson's disease (PD).

Methods – We treated twenty-eight demented patients with PD openly for 26 weeks with rivastigmine (mean daily dose 7.2 ± 3.3 mg/day). Baseline scores were compared with those at weeks 12, 26 and after 8 weeks of washout.

Results – Twenty patients completed 26 weeks of treatment and eight dropped out because of side effects. The Unified Parkinson's Disease Rating Scale mental subscore improved significantly at week 26 (P < 0.01) while the motor score (part III) did not change. The mean ADAScog total score improved by 7.3 points at week 26 (P < 0.002). The subscores for recognition, word finding, remembering instructions and concentration items of the ADAScog improved significantly as well (P < 0.02, P < 0.05, P < 0.005 and P < 0.003, respectively).

Conclusions – Rivastigmine may improve the cognitive functions in PD patients with dementia with no worsening of motor function.

Ancillary